Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
5 pending office actions • 5 art units • 5 examiners • 0 of 5 (0%) have an AI response strategy ready • 6 patents granted in the last 365 days
Impact Therapeutics (Shanghai), Inc. manages a patent portfolio in the Biotechnology & Pharmaceuticals technology area with 5 pending office actions. These actions are distributed across distinct examiners, meaning that each pending matter is being reviewed by a different individual. This distribution suggests a broad range of active inquiries across their pharmaceutical filings and indicates that the company is managing independent patent applications simultaneously.
The prosecution activity is further spread across 5 distinct art units, indicating that the company's innovations touch upon different specialized fields within biotechnology. KAHSAY HABTE is the busiest examiner for the portfolio, currently handling 1 pending office action. While this examiner is the busiest, they only manage 1 of the total pending actions, reflecting a decentralized prosecution environment. This diversity of examiners and art units means the company must navigate various examination styles and technical standards across its active portfolio.
Based on the USPTO statutory response window for each pending office action. 3 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Every pending office action with a known statutory deadline, placed on a days-until-due axis. Dots left of Today are overdue; the further right, the more runway. Cases that share a deadline window stack vertically. 3 of the docket's apps have a known mailing date.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Double-patenting + other | 2 (40%) |
| Multi-statute (no §101) | 2 (40%) |
| No statute on record | 1 (20%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| OTTON, ALICIA L | 1 | 64.9% | +9.4% |
| ABDALHAMEED, MANAHIL MIRGHANI ALI | 1 | 50.3% | +38.2% |
| BASQUILL, SEAN M | 1 | 38.8% | +21.7% |
| ISMAIL, REHANA | 1 | 75.8% | +34.8% |
| NESTOR, DONNA MICHELLE | 1 | 56.6% | +44.2% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18552434 | ORAL CAPSULE OF PARP INHIBITOR AND PREPARATION METHOD THEREOF | BASQUILL, SEAN M | 5d overdue |
| 18554980 | SUBSTITUTED FUSED BICYCLIC COMPOUNDS AS PARP INHIBITORS AND THE USE THEREOF | ABDALHAMEED, MANAHIL MIRGHANI ALI | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 4 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17769416 | DIHYDROIMIDAZO PYRIMIDO PYRIMIDINONE COMPOUND | NESTOR, DONNA MICHELLE | 25d overdue |
| 18552434 | ORAL CAPSULE OF PARP INHIBITOR AND PREPARATION METHOD THEREOF | BASQUILL, SEAN M | 5d overdue |
| 18259112 | SUBSTITUTED IMIDAZO[1,5-b]PYRIDAZINE COMPOUNDS AS KINASE INHIBITORS AND USE THEREOF | ISMAIL, REHANA | 7d |
| 18554980 | SUBSTITUTED FUSED BICYCLIC COMPOUNDS AS PARP INHIBITORS AND THE USE THEREOF | ABDALHAMEED, MANAHIL MIRGHANI ALI | — |
| Art Unit | Apps |
|---|---|
| 1699 | 1 |
| 1622 | 1 |
| 1614 | 1 |
| 1625 | 1 |
| 1627 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18687111 | SUBSTITUTED TRICYCLIC COMPOUNDS AS PARP INHIBITORS AND USE THEREOF | OTTON, ALICIA L | 1699 | §102§112DP | Final Rejection | — | Pending | Feb 27, 2024 |
| 18554980 | SUBSTITUTED FUSED BICYCLIC COMPOUNDS AS PARP INHIBITORS AND THE USE THEREOF | ABDALHAMEED, MANAHIL MIRGHANI ALI | 1622 | §102§112 | Non-Final OA | — | Pending | Oct 11, 2023 |
| 18552434 | ORAL CAPSULE OF PARP INHIBITOR AND PREPARATION METHOD THEREOF | BASQUILL, SEAN M | 1614 | §103§112 | Final Rejection | 5d overdue | Pending | Sep 25, 2023 |
| 18259112 | SUBSTITUTED IMIDAZO[1,5-b]PYRIDAZINE COMPOUNDS AS KINASE INHIBITORS AND USE THEREOF | ISMAIL, REHANA | 1625 | Other | Non-Final OA | 7d | Pending | Jun 23, 2023 |
| 17769416 | DIHYDROIMIDAZO PYRIMIDO PYRIMIDINONE COMPOUND | NESTOR, DONNA MICHELLE | 1627 | §103DP | Final Rejection | 25d overdue | Pending | Apr 15, 2022 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial